CD274 and neoplasm: BRCA1/2-mutated EOCs show a higher mutational load and a unique mutational signature with a significantly increased number of TILs, as well as elevated PD-1 expression or PD-L1 expression in tumor-associated immune cells compared to homologous recombination (HR)-proficient tumors.